Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study
Open Access
- 24 October 2024
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-11
Abstract
The characteristics of bronchiectasis (BE) in Asia, including Japan, remain largely unknown. We aimed to provide insights into the clinical characteristics and treatment outcomes of BE, especially regarding nontuberculous mycobacteria (NTM) infection and its poorly understood impact on prognosis. We also aimed to clarify the effect of long-term macrolide antibiotic use in patients with BE, who had no history of exacerbations. In this single-center, retrospective study, the medical records of patients who satisfied the BE criteria between January 1, 2012, and August 31, 2023, were reviewed. Severe exacerbations and mortality during the observation period were recorded. Baseline characteristics and overall survival of patients with and without NTM infection, and factors influencing the time to the first exacerbation and death were analyzed. Additionally, the effects of long-term macrolide antibiotic use in patients without a history of severe exacerbations were estimated. In a cohort of 1044 patients with BE, the rate of severe exacerbation was 22.3%, with mortality rates of 3.2% over 3 years. Notably, the high prevalence of NTM infection (n = 410, 39.3%) in this cohort was distinctive. NTM infection was not associated with either the time to first severe exacerbation (p = 0.5676, adjusted hazard ratio = 1.11) or mortality (p = 0.4139, adjusted hazard ratio = 0.78). Compared with the NTM group, the non-NTM group had a higher proportion of elevated inflammatory markers, with significant differences in C-reactive protein levels (p = 0.0301) and blood neutrophil counts (p = 0.0273). Pseudomonas aeruginosa colonization was more frequent in the non-NTM group (p = 0.0003). Among patients with non-NTM infection and without a history of exacerbation in the past 2 years, 38.2% received long-term macrolide antibiotics that did not invariably prolong the time to first severe exacerbation (p = 0.4517, IPW p = 0.3555). This study highlights BE epidemiology in Japan, noting that the presence of NTM infection may not necessarily worsen the prognostic outcomes and advising caution in the casual use of macrolides for milder cases without a history of exacerbations. UMIN Clinical Trials Registry Number: UMIN000054726 (Registered on 21 June 2024).Keywords
All Related Versions
Funding Information
- Japan Agency for Medical Research and Development (JP20fk0108129, JP21fk0108129h0702, JP21lm02007)
- Japan Society for the Promotion of Science (JP21K16118, JP21K08194)
- Takeda Science Foundation
- Uehara Memorial Foundation
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Japanese Respiratory Society
- Foundation of Kinoshita Memorial Enterprise
- Senri Life Science Foundation
- Japan Intractable Diseases Research Foundation (2020B02)
- Osaka Medical Research Foundation for Intractable Diseases
- Inamori Foundation
This publication has 36 references indexed in Scilit:
- Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomesScientific Reports, 2023
- Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)The Lancet Respiratory Medicine, 2023
- Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort studyThe Lancet Respiratory Medicine, 2021
- Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) studyRespiratory Medicine, 2021
- Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysisThe Lancet Respiratory Medicine, 2019
- The Bronchiectasis Severity Index and FACED score for assessment of the severity of bronchiectasisPulmonology, 2018
- Adult Patients With BronchiectasisChest, 2017
- An analysis of etiology, causal pathogens, imaging patterns, and treatment of Japanese patients with bronchiectasisRespiratory Investigation, 2015
- Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasisMolecular Immunology, 2013
- Bronchiectasis in secondary care: a comprehensive profile of a neglected diseaseEuropean Journal of Internal Medicine, 2003